Explore the Agenda

7:30 am Registration & Morning Coffee

8:20 am Chair’s Opening Remarks

Chief Commercial Officer (Cco), myTomorrows

Overcoming Regulatory Barriers to Deliver Timely Patient Access Worldwide

8:30 am Setting the Stage – Expanded Access in 2026: From Ethical Imperative to Strategic Necessity

Director - Expanded Access Programs & Policy, GE2P2 Global Foundation
  •  Discussing how EAPs have evolved since their inception, from ad hoc programs to strategic global tools
  • Highlighting the key forces shaping the landscape today: regulatory variability operational challenges, supply pressures, and the not-so-subtle shift toward data collection for regulatory purposes
  • How EAPs are redefining their role and impact as vehicles for generating Real World Data/Evidence in clinical development and commercialization

9:00 am Overcoming Access Barriers in Low & Middle-Income Countries: Operational Lessons from The Max Foundation Model

Vice President - Programs Operations, The Max Foundation
  • Highlighting the operational aspects and unique features of the Max Foundation’s access model
  • Contrasting The Max Foundation’s humanitarian model with traditional MAP and compassionate use frameworks
  • Navigating the unique operational realities of low- and middle-income countries – from infrastructure and supply chain to patient engagement
  • Addressing the holistic challenges of access: practical, political, and logistical considerations in scaling impact

9:30 am Operationalizing Expanded Access Programs in Challenging Regional Landscapes: Lessons from Central America & the Caribbean

Director - Market Access, AstraZeneca
  • Discussing unique regulatory and operational challenges in Central American and Caribbean healthcare systems
  • Outlining practical approaches for implementing EAPs in high-cost therapy areas, including oncology and rare disease
  • Building trust with stakeholders and navigating government/public payer systems to enable patient access
  • Lessons learned and opportunities to strengthen regional EAP frameworks going forward

10:00 am Session Reserved for Early Access Care

Right click on the image to save it to your computer.

10:30 am Morning Break & Speed Networking

Join our speed networking session, tailored for Expanded Access experts like yourself, to connect with fellow industry peers to facilitate a rapid yet meaningful exchange of insights and expertise. Elevate your networking experience during this session designed for impactful connecting within the space.

11:30 am Fireside Discussion: Navigating Global Differences & Business Decisions in Expanded Access Programs

Chief Operating Officer, Alkeus Pharmaceuticals, Inc.
Head of Governance, EMD Serono
  •  Compare regulatory frameworks and access pathways across the US (FDA), Europe (EMA), and other national systems such as France’s ATU
  • Explore how approaches to expanded access differ between large pharma and smaller biotech organizations.
  • Examine how companies assess the business case and operational feasibility of launching programs in emerging regions, including the Middle East and Latin America

Maximizing Value from Expanded Access: Collecting, Managing & Applying Real-World Data (RWD)

12:00 pm Fireside Discussion: Driving Smarter Decisions by Clarifying the Role of RWD in EAPs

Director - Expanded Access Programs & Policy, GE2P2 Global Foundation
Director, Managed Access Programs, Bristol Myers Squibb
  • Comparing how FDA, EMA, and national health authorities interpret the use of RWD in expanded and post-trial access programs
  • Examining differing company approaches, from limiting programs to treatment-only access to actively incorporating structured evidence generation
  • Exploring real-world examples of where regulators accepted or rejected RWD submissions in filings and approvals
  • Defining the boundaries of ethical and compliant RWD collection when patient care is the primary purpose

12:30 pm Reducing Burden & Increasing Efficiency When Collecting RWD

  • Determining the minimum set of data points required to ensure an EAP collects only ‘fit-for-purpose’ data
  • Designing efficient data capture models including data collected in routine clinical practices (EMR), retrospective chart reviews, companion studies run in parallel to EAPs, and integrated EAP protocols
  • Overcoming practical barriers including physician time constraints, absence of site contracts, and limited infrastructure for consistent data entry
  • Sharing case studies from companies that successfully streamlined RWD collection without compromising patient access or overwhelming sites

1:00 pm Lunch & Networking

2:00 pm Case Study: Using Real-World Data from a Compassionate Use Program to Support Regulatory Filing in an Ultra-Rare Disease

Senior Director - Clinical Trial Management, Regeneron Pharmaceuticals
Associate Manager - Medical Study Operations, Regeneron Pharmaceuticals
  • Examining a practical case study of how RWD was collected and applied support a regulatory submission in an ultra-rare indication
  • Highlighting lessons learned from challenges in data collection, validation, and integration across functions
  • Exploring how insights from RWD informed patient access, program design, or engagement with stakeholders
  • Providing actionable takeaways for translating RWD into strategies that enhance EAP efficiency and impact

Driving Efficiency & Compliance Across the EAP Supply Lifecycle

2:30 pm Leveraging AI to Enhance Operational Efficiency in Expanded Access Programs

Senior Global Manager, Managed Access Programs, Sanofi
  • Addressing compliance considerations using AI to flag operational risks and red flags early in the process
  • Leveraging data analytics to reshape programs around unmet medical needs, geographic distribution, and demographic insights to improve patient access
  • Exploring AI applications for patient eligibility assessment, supply forecasting, and resource management

3:00 pm Session Reserved for myTomorrows

Mytomorrows.png

3:30 pm Afternoon Break & Networking

4:15 pm Managing Complex Clinical Supply Chain in Unpredictable EAP Scenarios

Senior Manager - Global Clinical Supply Chain, Takeda Pharmaceutical
  • Case study: Maintaining patient treatment in Israel during conflict
  • Highlighting issues/regions without a defined EAP framework
  • Coordinating supply with EAP vendors. Navigating label regulatory ambiguity when clinical trial programs wind down, assets transfer, or treatment continues beyond planned timelines to maintain patient access
  • Discussing practical lessons from a pharmacist’s end-user perspective to streamline investigations drug service operations and patient delivery

Post-Trial Access Made Practical: Navigating Operations, Compliance, & Global Complexity

4:45 pm Operationalizing Post-Trial Access: From Trial Close to Seamless Delivery

Executive Director & Consultant - Expanded, Continued Access, Product Delivery, Clinical Trial Commercial Product Strategy & Pr, Eli Lilly & Co.
  • Aligning internal teams, vendors, and stakeholders to manage supply, labeling, and distribution efficiently
  • Forecasting patient demand post-trial and planning logistics to avoid delays or stock-outs
  • Implementing practical tracking, communication, and reporting mechanisms for multi-country programs
  • Learning from real-world examples of successful PTA execution to reduce operational burden and maintain compliance

5:15 pm Chair’s Closing Remarks

Chief Commercial Officer (Cco), myTomorrows

5:20 pm End of Conference Day One